Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
Shoreline Biosciences to Present at Upcoming Investor Conferences
San Diego, Calif., September 8, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires
San Diego, Calif., July 13, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Shoreline Biosciences Appoints Mohammad El-Kalay, Ph.D. as Senior VP and Head of CMC
San Diego, Calif., June 28, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Kite and Shoreline Biosciences Enter Into Strategic Partnership To Develop Novel Allogeneic Cell Therapies
— Partnership Follows Kite’s Investment in Shoreline’s Recent Series A Financing — Santa Monica, Calif., and San Diego, June 17, 2021 – Kite, a Gilead
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
SAN DIEGO, CA, CAMBRIDGE, MA & BEIJING, China – June 9, 2021 — Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted
Shoreline Biosciences Appoints Kimberly Manhard to Board of Directors
San Diego, Calif., May 19, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK)